Ruiz-Delgado GJ, Ruiz-Argüelles GJ, Ruiz-Reyes G

Language: Spanish
References: 25
Page: 345-348
PDF size: 130.76 Kb.

ABSTRACT

Dasatinib (BMS-354825) is an inhibitor of tirosin kinases (BCR-ABL), SRC kinases and other oncogenic kinases. Is able to inhibit 18 of 19 BCR/ABL mutations of kinases resistant to its predecessor, imatinib. It prevents the overproduction of the cancerous cells in the marrow of the patients with chronic granulocytic leukemia or linfoblastic acute leukemia with Philadelphia+ chromosome who had shown resistance or intolerance to previous treatments with imatinib or nilotinib.

REFERENCES

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.

2. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824-30.

3. Druker BJ, Talpaz M, Resta DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.

4. Kantarjian H, Sawyers C, Hochhaus A. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.

5. O’Brien SG, Guilhot F, Larson RA, Gathman I, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.

6. Silver RT, Talpaz M, Sawyers CLl. Four years follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood 2004; 104:11(Abstract 23).

7. Guilhot F. Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: update from the IRIS Study. Blood 2004;104:10(Abstract 21).

8. Hughes TP, Kaeda J, Branford S, Rudzki Z, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.

9. Graham SM, Jorgensen HG, Allan E, Pearson C, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25.

10. Bhatia R, Holtz M, Niu N, Gray R, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7.

11. Gorre ME, Mohammed M, Ellwood K, Hsu N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.

12. Shah NP, Nicoll JM, Nagar B, Gorre ME, et al. Multiple BCRABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.

13. Branford S, Rudzki Z, Walsh S, Grigg A, et al. High frequency of point mutations clustered within the adenosine triphosphate- binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002;99:3472-5.

14. Shah NP, Tran C, Lee FY, Chen P, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004:305:399-401.

15. Lombardo IJ, Lee FY, Chen P, Norris D, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)- 2- methylpyrimidin-4- amino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61.

16. Tokarski J, Newitt J, Lee F, Lombardo L, et al. The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood 2004;104:553(Abstract).

17. Carter TA, Wodicka LM, Shah NP. Inhibition of drug resistantmutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-6.

18. O´Hare T, Walters DK, Stoffregen EP, Jia T, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5.

19. Weisberg E, Manley PW, Breitenstein W, Brüggen J, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.

20. Cortes J, Rousselot P, Kim DW, Ritchie E, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207-3213.

21. Guilhot F, Apperley J, Kim D-W, Bullorsky EO, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukaemia in accelerated phase. Blood 2007,109(10):4143-50.

22. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109(6):2303-9.

23. Quintas-Cardama A, Kantarjian H, Jones D, Nicaise C, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome- positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109(2):497-9.

24. Talpaz M, Shah NP, Kantarjian H, Donato N, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531-41

25. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A, Gutiérrez-Aguirre CH, et al (Latin American Cooperative Oncohematology Group). The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005;36:1043-7.